Paper1978477
Experiences of long-term treatment with remoxipride: efficacy and tolerability.
Wålinder J and 1 other. Acta Psychiatr Scand Suppl, 1990. Cited by 26 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Experiences of long-term treatment with remoxipride: efficacy and tolerability. Papers, record 1978477. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1978477
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antipsychotic Agents | Major topic |
| Benzamides | Major topic |
| Schizophrenia | Major topic |
| Schizophrenic Psychology | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Chronic Disease | |
| Double-Blind Method | |
| Dyskinesia, Drug-Induced | |
| Female | |
| Haloperidol | |
| Humans | |
| Long-Term Care | |
| Male | |
| Middle Aged | |
| Psychiatric Status Rating Scales | |
| Remoxipride |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 9,098,656 | Drug-induced movement disorders. | Drug Saf | 1997 | https://conductscience.org/library/papers/9098656 | PubMed |
| 8,935,806 | Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system? | Psychopharmacology (Berl) | 1996 | https://conductscience.org/library/papers/8935806 | PubMed |
| 8,736,614 | Adverse effects of antipsychotic agents. Do newer agents offer advantages? | Drugs | 1996 | https://conductscience.org/library/papers/8736614 | PubMed |
| 8,329,149 | Tolerability of remoxipride in the long term treatment of schizophrenia. An overview. | Drug Saf | 1993 | https://conductscience.org/library/papers/8329149 | PubMed |
| 8,099,797 | Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. | J Neural Transm Gen Sect | 1993 | https://conductscience.org/library/papers/8099797 | PubMed |
| 7,506,647 | Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. | Drugs | 1993 | https://conductscience.org/library/papers/7506647 | PubMed |
| 1,981,869 | Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. | Drugs | 1990 | https://conductscience.org/library/papers/1981869 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1978477
GET https://conductscience.org/api/papers/v1/1978477/authors